严重急性呼吸道感染准备:病毒性呼吸道感染多中心前瞻性队列研究方案
该方案描述了一项前瞻性多中心队列研究,纳入由可导致暴发、流行和大流行的呼吸道病毒(包括严重急性呼吸综合征冠状病毒2)所致严重急性呼吸道感染的住院患者,收治于急性护理病房或ICU,来自美国至少15家医院。研究无干预,收集人口学、体征症状、用药、微生物学、影像学、机械通气、医院操作及临床结局与医院压力等数据,标本于入组第0天、第3天、第7–14天及出院时采集。主要终点为入院后前30天内连续无机械通气存活天数(VFD),次要终点包括急性肾损伤、休克、肝衰竭、弥散性血管内凝血前的无器官衰竭天数、28天死亡率、适应性免疫及免疫学与微生物学结局。研究由重症医学学会Discovery、Resilience Intelligence Network与国家新发特殊病原体培训和教育中心协作开展,旨在增进对预后因素和资源利用的理解。
要点
- SARI-Preparedness为前瞻性多中心队列,纳入美国至少15家医院急性护理病房或ICU中由呼吸道病毒所致严重急性呼吸道感染患者。
- 主要终点为入院后前30天内连续无机械通气存活天数(VFD)。
- 关键次要终点包括急性肾损伤、休克、肝衰竭、弥散性血管内凝血前的无器官衰竭天数及28天死亡率。
- 标本采集时间为入组第0天、第3天、第7–14天及出院时。
- 研究无干预,同时收集医院压力数据以评估资源利用。
适用人群与场景
- 由可导致暴发、流行和大流行的呼吸道病毒(包括严重急性呼吸综合征冠状病毒2)感染所致严重急性呼吸道感染、收治于急性护理病房或ICU的患者。
- 来自美国至少15家医院、代表不同地理区域的多中心队列。
研究设计与关键结果
- 研究设计为前瞻性队列研究,计划纳入来自美国至少15家医院急性护理病房或ICU的严重急性呼吸道感染患者。
- 研究无干预,测量包括人口学、体征、症状、药物、微生物学、影像学及相关检查、机械通气、医院操作及其他干预、临床结局与医院压力。
- 标本于入组第0天、第3天、第7–14天及出院时采集。
- 主要结局为入院后前30天内连续无机械通气存活天数(VFD)。
- 重要次要结局包括急性肾损伤、休克、肝衰竭、弥散性血管内凝血前的无器官衰竭天数、28天死亡率、适应性免疫以及免疫学和微生物学结局。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究方案。
- 研究由重症医学学会Discovery、Resilience Intelligence Network与国家新发特殊病原体培训和教育中心协作开展。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该方案旨在增进对与更差结局和资源利用增加相关的预后因素的理解,从而可能引出减轻严重急性呼吸道感染相关呼吸道病毒感染临床影响的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Respiratory virus infections cause significant morbidity and mortality ranging from mild uncomplicated acute respiratory illness to severe complications, such as acute respiratory distress syndrome, multiple organ failure, and death during epidemics and pandemics. We present a protocol to systematically study patients with severe acute respiratory infection (SARI), including severe acute respiratory syndrome coronavirus 2, due to respiratory viral pathogens to evaluate the natural history, prognostic biomarkers, and characteristics, including hospital stress, associated with clinical outcomes and severity.
DESIGN: Prospective cohort study.
SETTING: Multicenter cohort of patients admitted to an acute care ward or ICU from at least 15 hospitals representing diverse geographic regions across the United States.
PATIENTS: Patients with SARI caused by infection with respiratory viruses that can cause outbreaks, epidemics, and pandemics.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Measurements include patient demographics, signs, symptoms, and medications; microbiology, imaging, and associated tests; mechanical ventilation, hospital procedures, and other interventions; and clinical outcomes and hospital stress, with specimens collected on days 0, 3, and 7-14 after enrollment and at discharge. The primary outcome measure is the number of consecutive days alive and free of mechanical ventilation (VFD) in the first 30 days after hospital admission. Important secondary outcomes include organ failure-free days before acute kidney injury, shock, hepatic failure, disseminated intravascular coagulation, 28-day mortality, adaptive immunity, as well as immunologic and microbiologic outcomes.
CONCLUSIONS: SARI-Preparedness is a multicenter study under the collaboration of the Society of Critical Care Medicine Discovery, Resilience Intelligence Network, and National Emerging Special Pathogen Training and Education Center, which seeks to improve understanding of prognostic factors associated with worse outcomes and increased resource utilization. This can lead to interventions to mitigate the clinical impact of respiratory virus infections associated with SARI.
参考来源
- Postelnicu R, Srivastava A, Bhatraju PK, et al. Severe Acute Respiratory Infection-Preparedness: Protocol for a Multicenter Prospective Cohort Study of Viral Respiratory Infections. Crit Care Explor. 2022. PMID: 36284548. doi:10.1097/CCE.0000000000000773
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。